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Heart  rate  is a predictor  of  cardiovascular  and  all-cause  mortality  in  the  general  population  and  in patients
with cardiovascular  disease.  Increased  resting  heart  rate  multiplies  risk  and  interferes  at all  stages  of  the
cardiovascular  disease  continuum  initiating  from  endothelial  dysfunction  and  continuing  via atheroscle-
rotic  lesion  formation  and plaque  rupture  to  end-stage  cardiovascular  disease.  As  a therapeutic  target,eywords:
eart rate
ardiovascular disease continuum
(f) current inhibition
isk reduction
heart rate  is  accessible  via  numerous  pharmacological  interventions.  The  concept  of selective  heart  rate
reduction  by  the  I(f) current  inhibitor  ivabradine  provides  an  option  to  intervene  effectively  along  the
chain  of events  and  to deﬁne  the  speciﬁc  and  prognostic  role  of heart  rate  for  patients  with  coronary
artery  disease  and heart  failure.  Future  interventional  studies  will further  clarify  the  signiﬁcance  of
heart  rate  and targeted  heart  rate  reduction  for  primary  and  secondary  prevention  in cardiovascular
ts.
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Based on the evidence from epidemiological and clinical studies
esting heart rate developed from an ordinary clinical variable to a
elevant cardiovascular risk marker. The impact of increased rest-
ng heart rate on prognosis is validated in the general population,
n patients with hypertension, coronary artery disease (CAD), or
eart failure and exists irrespective of age, cardiovascular risk fac-
ors, or comorbidities [1–7]. The cardiovascular disease continuum
ncludes risk factors initiating a process leading to tissue damage
nd a subsequent chain of events resulting in end-stage cardiovas-
ular disease [8]. From vascular risk factors to cardiovascular events
nd heart failure, heart rate affects basically all stages of the car-
iovascular continuum and has therefore evolved as a relevant risk
arker and goal of therapy in cardiovascular prevention and dis-
ase [1,9]. The aim of the following article is to elucidate the close
onnection and the impact of heart rate on the different entities
f the cardiovascular continuum and how a targeted reduction of
eart rate may  prevent cardiovascular events (Fig. 1).
esting heart rate and outcome in patients with risk factorsMany epidemiological and clinical studies investigated the
ssociation between resting heart rate and outcomes in popula-
ions with and without existing cardiovascular risk factors. In the
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Framingham study, cardiovascular mortality increased progres-
sively with resting heart rate in a population free from
cardiovascular disease. The effect of heart rate on mortality was
independent of other cardiovascular risk factors [2] and risk further
increases with additional risk factors such as arterial hyperten-
sion [3]. Prospective studies in healthy populations showed that
increased resting heart rate may  predispose to the development
of impaired glucose metabolism, obesity, and diabetes mellitus
[10,11].
A fundamental association between heart rate and development
of arterial hypertension was already shown in a retrospective anal-
ysis of military personnel following combat during World War  I
[12]. Since then a relevant association between cardiovascular mor-
tality and resting heart rate in patients with hypertension was
shown by several investigations. The HARVEST study established a
strong link between higher heart rates and increases in blood pres-
sure in a cohort of stage 1 hypertensive patients [13]. Patients in this
cohort whose heart rate was persistently elevated during the study
period of 6.4 years had a doubled fully adjusted risk of developing
ﬁxed hypertension compared with individuals with normal heart
rates. In hypertensive persons of the Framingham cohort the rate of
complications caused by cardiovascular events as well as the total
mortality increased by about 100% when heart rate increased by
40 beats/min [3]. In patients with arterial hypertension, microal-
buminuria increases cardiovascular risk and may  be regarded as
a marker of generalized vascular injury [14]. A potential connec-
tion between the prevalence of microalbuminuria and heart rate
in hypertensive patients was analyzed in I-SEARCH [15]. In this
outpatient cohort, heart rate was found to be a strong predictor
vier Ltd. All rights reserved.
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dFig. 1. Pathophysiological effects of heart
or the prevalence of microalbuminuria, even after adjustment for
ypertension and risk factors such as pre-existing cardiac disease,
iabetes mellitus, age, and sex. A consecutive analysis showed that
he prevalence of microalbuminuria is even higher in hypertensive
atients with a history of atrial ﬁbrillation [16].
eart rate promotes atherosclerosis
Experimental and clinical data suggest that sustained elevation
f heart rate – independent of the underlying trigger – contributes
o the pathogenesis of vascular disease. In animal studies, accel-
rated heart rate was associated with vascular oxidative stress,
ndothelial dysfunction, acceleration of atherogenesis, and vas-
ular stiffness [1]. Since the early 1980s a broad range of animal
tudies investigated effects of selective heart rate reduction on vas-
ular phenotypes in several animal models. Heart rate reduction
y electrophysiological (sinus node ablation) and pharmacologi-
al [I(f) current inhibition] interventions reduced atherosclerosis
n monkeys and dyslipidemic mice [17,18]. Treatment with the
(f) current inhibitor ivabradine reduced vascular oxidative stress
nd inﬂammation, restored endothelial function, and augmented
ascular compliance in ApoE−/− mice [19–24].
In humans, accelerated resting heart rate was  shown to be
losely linked to systemic inﬂammation and markers of endothe-
ial dysfunction [25,26]. However, despite extensive experimental
vidence, clinical data investigating the effects of heart rate reduc-
ion on endothelial function are not yet conclusive. While heart
ate was positively associated with brachial artery ﬂow-mediated
ilation (FMD) in a Framingham cohort [27], a prospective study
n patients with diabetes mellitus did not show a positive effect of
eart rate reduction induced by ivabradine on FMD  [28].
Beyond the classical factors perturbing endothelial function
ike oxidative stress or inﬂammation vascular integrity may  be
ffected by local hemodynamic characteristics deﬁned by heart rate
uch as endothelial shear stress [29] or cyclic tensile stress [30].
s an integral component of cyclic stress (pulse pressure × heart
ate), heart rate controls vascular function and deﬁnes trans-
ural force imposed by pulsatile blood ﬂow. Accelerated heart
ate may  promote low and oscillatory endothelial shear stress.
isturbed shear stress and enhanced tensile stress may  synergis-
ically promote atherogenesis and vascular stiffness [31]. However
s heart rate dependent effects on atherosclerosis are discussed
y several authors, experimental evidence on the exact rate-
ependent changes of the local hemodynamic environment andHeart Failure 
n the cardiovascular disease continuum.
the subsequent molecular signaling is sparse and still has to be
characterized.
Heart rate in coronary heart disease and myocardial
infarction
The prognostic importance of resting heart rate for morbid-
ity and mortality in patients without cardiovascular disease also
applies to populations with established CAD and after myocar-
dial infarction. Studies such as CASS and BEAUTIFUL demonstrated
a positive association between increased resting heart rate and
cardiovascular mortality [4,32]. In BEAUTIFUL, patients with CAD
and left ventricular systolic dysfunction and a resting heart rate
>70 bpm displayed increased cardiovascular mortality as well as
an increased risk for hospitalization due to heart failure, myocar-
dial infarction, or need for coronary revascularization. Moreover,
increased resting heart rate was associated with coronary vascular
events [33]. This ﬁnding may  be explained by increased occurrence
of coronary plaque disruption since heart rate is a predictor for
instability of coronary plaque [34]. Prognosis of patients after a
myocardial infarction is closely linked to heart rate. Patients with
myocardial infarction exhibit an increased resting heart rate and in
particular the heart rate assessed at hospital discharge correlates
with an increase in mortality rate after 1 year [6]. Metaanalyses
of the GISSI-2 and 3 trials including about 20,000 patients demon-
strated that in-hospital mortality rate of patients after myocardial
infarction signiﬁcantly rises from 3.3% to 10.1% when patients with
heart rates <60 bpm were compared with those with heart rates
>100 bpm on admission [35]. The GISSI-trials showed that even
patients without heart failure and an elevated heart rate had a
worse long-term survival prognosis [35].
Heart rate is a major determinant of myocardial oxygen demand
and coronary blood ﬂow [36]. In CAD, heart rate becomes relevant
affecting both sides of myocardial oxygen balance. An increased
heart rate contributes to an imbalance by both decreasing supply
and increasing demand thereby leading to myocardial ischemia
and subsequent angina. Since the advent of beta-blockers, phar-
macological heart rate reduction may  be seen as a cornerstone
of symptomatic (anti-anginal) treatment of CAD patients. Today
beta-blockade remains the standard of care for CAD patients par-
ticularly after a myocardial infarction [37,38]. However, as recently
published data from the REACH registry show, beta-blocker use
in patients with CAD (+/− myocardial infarction) was not asso-
ciated with a lower event rate [39]. Data from the prospective
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trial aimed at evaluating associations of the resting heart rate at
baseline with cardiovascular and neurological outcomes among
patients who experienced an ischemic stroke [56]. Patients after
a ﬁrst stroke and a baseline heart rate ≥76 bpm had a higher risk
HR (95% CI), 0.82 (0.75–0.90) 
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LARIFY registry show that in outpatients with stable CAD despite
 widespread use of beta-blockers, patients often have resting
R ≥70 bpm, which is associated with an overall worse health
tatus, more frequent angina, and ischemia [40]. With the con-
ept of I(f) current inhibition, a new treatment option expanded
nti-anginal drug treatment. Ivabradine, an I(f) current inhibitor,
nduces a sustained and dose-dependent reduction of heart rate at
est and during exercise, without relevant effects on left ventricular
LV) contractility, blood pressure, and atrioventricular conduc-
ion [41]. The anti-anginal and anti-ischemic efﬁcacy of ivabradine
 in monotherapy or in combination with a beta-blocker – has
een demonstrated by several clinical trials [42–44]. As a conse-
uence, the substance evolved as an alternative strategy especially
or patients in whom the use of beta-blockers is limited due to
ide effects or patients who remain symptomatic despite beta-
lockade. Regarding the above-mentioned registry based results,
urther research is necessary to identify patients with CAD and
fter myocardial infarction who may  beneﬁt from co-treatment
ith ivabradine.
esting heart rate and outcome in heart failure
In patients with heart failure increased sympathetic activity
s associated with a positive chronotropic stimulation leading to
ccelerated resting heart rate [45]. Heart rate may  directly affect
yocardial performance by alteration of oxygen consumption,
eduction of diastolic ﬁlling and coronary perfusion by impair-
ent of relaxation, and ﬁnally by pro-arrhythmic effects [46].
urthermore, high heart rates per se can cause heart failure [47].
he signiﬁcance of heart rate on mortality was retrospectively
ddressed in sub-analyses of several heart failure trials which
nrolled a total of almost 10,000 patients with advanced systolic
eart failure (New York Heart Association class II–IV). The general
rend of these trials clearly demonstrates that high heart rate at rest
ontributes to poor survival and represents a negative prognostic
redictor [48]. In the CIBIS and CIBIS II trials (Cardiac Insufﬁciency
isoprolol Study), heart rate and heart rate change both were signif-
cant predictors of mortality [49,50]. However, it remains currently
nknown whether or to what extent the beneﬁt from beta-blockers
n patients with heart failure is due to heart rate reduction per se or
ther beneﬁcial effects deriving from interruption of maladaptive
eta-signaling pathways. Two metaanalyses investigated whether
he survival beneﬁts of beta-blockade in heart failure are associ-
ted with the magnitude of heart rate reduction or the beta-blocker
ose. Both showed a close relation of outcome with the extent of
ate reduction rather than with the achieved dosage [48,51]. In view
f these ﬁndings interventional trials pursuing a concept of “selec-
ive” heart rate reduction seemed a logical consequence to provide
urther information on the prognostic role of heart rate in chronic
eart failure. Post hoc analyses of two large scale prospective trials
 the BEAUTIFUL and the SHIFT trials – investigating the effects of
elective heart rate reduction with ivabradine identiﬁed heart rate
s a modiﬁable risk factor in patients with heart failure [5,32,33,52].
n BEAUTIFUL, elevated heart rate (70 bpm or more) was a strong
ndependent risk factor in patients with CAD and LV dysfunction a
nding that was conﬁrmed by the SHIFT cohort in patients with an
V ejection fraction of <35% and a heart rate of 70 bpm or higher.
Whereas both trials established a strong prognostic role for
eart rate in heart failure, the results of the primary analyses turned
ut differently. Treatment with ivabradine on top of standard med-
cation did not reduce the primary composite endpoint in patients
ith stable angina, left ventricular dysfunction (ejection fraction
40%), and heart rate ≥60 bpm in the BEAUTIFUL trial. However, it
id reduce secondary endpoints (admission to hospital for fatal and
on-fatal myocardial infarction, coronary revascularization) in aiology 62 (2013) 183–187 185
subgroup of patients with heart rate of 70 bpm or greater. The SHIFT
trial included patients with left ventricular dysfunction (ejection
fraction ≤35%), both ischemic (68%) and non-ischemic (32%) and a
heart rate ≥70 bpm. Heart rate reduction by ivabradine reduced the
risk for the primary composite endpoint by 18% (Fig. 2). This result
was mainly driven by hospital admissions for worsening heart fail-
ure and occurred within the ﬁrst 3 months after start of treatment.
Moreover heart rate reduction with ivabradine reduced death from
heart failure and hospital admissions for worsening heart failure
and any other cardiovascular hospital admissions. A recently pub-
lished secondary analysis of the SHIFT study showed that the effect
of ivabradine on outcomes was  most pronounced in patients with
a baseline heart rate of ≥75 bpm. Risk reduction depended on heart
rate with the best protection for heart rates <60 bpm or reduc-
tions >10 bpm on treatment with ivabradine. On  the basis of this
evidence the current ESC guidelines acknowledge the prognostic
relevance of heart rate and consider ivabradine as add-on therapy
in patients with severe left ventricular dysfunction (ejection frac-
tion <35%) and a heart rate above 70 bpm despite treatment with a
beta-blocker.
Resting heart rate and neurological outcomes
Whereas the intrinsic heart rate at rest is predictive for cardio-
vascular morbidity and mortality in the general population and in
patients with cardiovascular disease no such association is known
for neurological disease and ischemic stroke. As a consequence
of a broad range of experimental data demonstrating a close link
between heart rate and vascular function and phenotype recent
studies focused on the effects of heart rate reduction on the cerebral
vasculature and circulation. Conservation of endothelial homeo-
stasis represents a prerequisite and a basic mechanism of stroke
protection in mice, as shown by experimental studies [53,54]. In
a model of mice subjected to chronic mental stress, stressed ani-
mals displayed higher resting heart rates, impaired endothelial
function, and an increase in experimental stroke size. In turn a
reduction of resting heart rate with ivabradine in stressed mice
restored endothelial function and protected from ischemic brain
injury via reduction of stroke size [55]. In a model of dyslipidemic
mice chronic heart rate reduction via ivabradine maintained cere-
bral endothelial function and prevented cerebral artery remodeling
[24]. Inspired by these ﬁndings a post hoc analysis of the PROFESS
(The Prevention Regimen for Effectively Avoiding Second Stroke)Month  
Fig. 2. Primary combined endpoint* of the SHIFT trial [52] (*composite of cardio-
vascular death or hospital admission for worsening heart failure).
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f total death, vascular death, and non-vascular death. No sig-
iﬁcant association was found with recurrent stroke, myocardial
nfarction, and new onset or worsening congestive heart failure.
 striking ﬁnding was a signiﬁcant association between heart rate
nd functional neurological outcomes after a recurrent stroke. Poor
unctional independence according to the Barthel index score and
ognitive decline according to the Mini-Mental State Examination
MMSE) score were signiﬁcantly associated with an increasing rest-
ng heart rate. Low resting heart rate was associated with a better
unctional outcome and less cognitive decline (Fig. 3). Although
reliminary and hypothesis-generating these results identify heart
ate as mediator of cerebrovascular effects and may  suggest heart
ate as a potential novel target of intervention for improvement in
erebrovascular function after ischemic events.
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ig. 3. Effects of resting heart rate on daily life activities and cognitive function in the
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Summary
Increased resting heart rate interferes at all stages of the cardio-
vascular disease continuum. Heart rate may  add to the pathogene-
sis of arterial hypertension or diabetes, increase the cardiovascular
risk in patients with these diseases, and deﬁne mortality and
morbidity in patients with CAD and heart failure. Heart rate reduc-
tion improves vascular function and prevents atherosclerosis in
an experimental setting and is thus characterized as a potential
modiﬁable risk factor by some authors. However an essential pre-
requisite to meet the criteria as a risk factor – interventional studies
demonstrating a modulation of risk by heart rate reduction – are
still lacking. If heart rate reduction may  reduce risk in patients with
established risk factors remains an open question. As a therapeutic
target heart rate is accessible via pharmacological interventions.
Beyond long established substances such as beta-blockers the con-
cept of “pure” heart rate reduction via inhibition of I(f) currents in
the sinoatrial node was implemented in recent years. A multitude
of interventional studies tested the concept of selective heart rate
reduction by ivabradine both for symptomatic and prognostic treat-
ment in CAD and in heart failure. In patients with coronary artery
disease, heart rate reduction with the I(f) current inhibitor ivabra-
dine potently prevents angina and ischemia at rest and during exer-
cise and today expands the armamentarium for the symptomatic
treatment of chronic CAD. Although selective heart rate reduction
with ivabradine led to some beneﬁcial effects in patients with stable
angina and left ventricular dysfunction, a clear prognostic beneﬁt
could not be established. Whereas in patients with chronic heart
failure and a more severe reduction in left ventricular function
(ejection fraction <35%) treatment with ivabradine improved clin-
ical outcomes and established a role for heart rate as a modiﬁable
risk factor in chronic heart failure. Although not a primary com-
ponent of the cardiovascular continuum, cerebrovascular ischemic
events and stroke share a large part of the underlying mecha-
nisms contributing to cardiovascular events. Results obtained in
animal models demonstrate beneﬁcial effects of pharmacologi-
cal heart rate reduction with ivabradine on vascular function and
stroke size. Post hoc analyses of patients after a ﬁrst stroke demon-
strate an association between functional neurological outcomes
and resting heart rate. Thus, selective heart rate reduction may
play a future role in secondary prevention after cerebrovascular
events.
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